Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dude, NF2R6 is like a Jimmy Page solo
Most are holding, just the cub scouts trading back and forth
They would have to dilute to raise the matching amount, just digging a hole
Most grants are matching fund grants. If u don't have the matching funds you can't accept, plus usually u have to share knowledge obtained during grant study
Getting all the ducks in order prior to results, commercialization, buyout
Which mens you sold and are hoping to come back in cheaper
Guitar Frets that won't wear down, nice
but how much is a fret worth, well, not to fret over it for now
Money came in before they could wrap up transaction before 10Q, expect PR announcing purchase
I watched it 2500 times, I accidentally hit replay continuously button
Like I said, that picture looks like Koos a nd Lander are holding the winning Lottery ticket
Picture looks like they have a winning lotto ticket
Nice write up
NIH is funded from your taxes, they don't give money to companies. RGBP is getting their work done by the government, they don't need funding.
Nothing ever ends in govt
New spin off company, hmm
Check it under Nasdaq after hrs shows 249500 shares bought bringing price to .4892
Agree, holding
I think it will BE too
29.8 b
aDVISE TO UNLOAD bmsn AND entb AND PUT INTO rgbp
With the news lately, they would be better off holding for much larger gains in a year, rather than acting like a Kansas day trader and selling for chump change.
In the long run, those getting cheaper shares will add to their bounty at the current price based on progress they see and long term outlook. In fact, they may become the whales as more progress is laid out.
not worried or concerned
I'm sure people are moving money to buy the rest of the week after being caught off guard with today's news
if that were true the pps would be $45
true, it's only 4:30 am in Hawaii
predicting Dividend Shares will be given a price by New Years
most of the shareholders and small time, small mind people, if they make $100, they wet their pants and sell
Monitor the business news channels today, see if they pick up the story
You know who is buying and selling? Amazing
Or could be the same flippers selling here and buying banned and back and forth again and again
Everyone is about to load up, everyone
Who did you talk to?
People buy all common names and company product names in order to own the domain name which they are hoping will be bought off them by the company for 100X what they paid.
Sometimes when making predictions you have to do the buying
A big room with an echo
The top researcher is still here on contract, so that makes TWO Top Researchers, plus Christine
looking good here
FDA Launches Orange Book Mobile Application
FDA and CDER have launched a mobile application (app) to put timely information about generic drugs in the hands of those using smartphones and tablets. The new app makes it easy and convenient to view The Approved Drug Products with Therapeutic Equivalence Evaluations list. This list is most commonly known as the “Orange Book.”
The Orange Book Express mobile app provides users with a mobile-friendly way to identify drug products approved on the basis of safety and effectiveness by the Agency, as well as information about patents and exclusivity. It allows them to search both the Active Ingredient and Proprietary Name fields at once, without searching separately for each marketing status for prescription, over-the-counter, and discontinued products. Users can also search by patent number without specifying a marketing status. The app will differ from the full Web version of the Orange Book in that the ability to filter results and search for text within results will be unavailable via data download.
Orange Book users include pharmacists, prescribers, industry, Agency employees, and third-party payers. Industry personnel refer to the Orange Book for its patent pages and product-specific exclusivity information, and to determine reference standards or drugs for performing their bioequivalence studies. Third-party payers, pharmacists, and prescribers use the Orange Book to determine appropriate generic drug substitution.
The Orange Book first appeared as a print publication in October 1980. Today “Orange Book” is one of the most searched-for terms on FDA.gov.
The Orange Book Express mobile app reflects our commitment to keep up with the latest technologies, developing effective means for the public to access important and useful information about generic drugs. The app also makes the Orange Book available to a wider audience than ever before – supporting users who may not always have convenient access to a computer or wired Internet connection.
I would like to sincerely thank the Office of Generic Drugs and the Office of Communications for their innovative efforts to bring us to another significant milestone in generic drug history. As a result of their work, easy access to real-time information about generics is available. This is especially important for health care professionals who rely on this information in protecting their patients’ health and providing consumers with alternatives to brand name drugs.
For more information about the new mobile app, including links for free download via iTunes or Google Play Store, visit Orange Book.
FDA Launches Orange Book Mobile Application
FDA and CDER have launched a mobile application (app) to put timely information about generic drugs in the hands of those using smartphones and tablets. The new app makes it easy and convenient to view The Approved Drug Products with Therapeutic Equivalence Evaluations list. This list is most commonly known as the “Orange Book.”
The Orange Book Express mobile app provides users with a mobile-friendly way to identify drug products approved on the basis of safety and effectiveness by the Agency, as well as information about patents and exclusivity. It allows them to search both the Active Ingredient and Proprietary Name fields at once, without searching separately for each marketing status for prescription, over-the-counter, and discontinued products. Users can also search by patent number without specifying a marketing status. The app will differ from the full Web version of the Orange Book in that the ability to filter results and search for text within results will be unavailable via data download.
Orange Book users include pharmacists, prescribers, industry, Agency employees, and third-party payers. Industry personnel refer to the Orange Book for its patent pages and product-specific exclusivity information, and to determine reference standards or drugs for performing their bioequivalence studies. Third-party payers, pharmacists, and prescribers use the Orange Book to determine appropriate generic drug substitution.
The Orange Book first appeared as a print publication in October 1980. Today “Orange Book” is one of the most searched-for terms on FDA.gov.
The Orange Book Express mobile app reflects our commitment to keep up with the latest technologies, developing effective means for the public to access important and useful information about generic drugs. The app also makes the Orange Book available to a wider audience than ever before – supporting users who may not always have convenient access to a computer or wired Internet connection.
I would like to sincerely thank the Office of Generic Drugs and the Office of Communications for their innovative efforts to bring us to another significant milestone in generic drug history. As a result of their work, easy access to real-time information about generics is available. This is especially important for health care professionals who rely on this information in protecting their patients’ health and providing consumers with alternatives to brand name drugs.
For more information about the new mobile app, including links for free download via iTunes or Google Play Store, visit Orange Book.
FDA Launches Orange Book Mobile Application
FDA and CDER have launched a mobile application (app) to put timely information about generic drugs in the hands of those using smartphones and tablets. The new app makes it easy and convenient to view The Approved Drug Products with Therapeutic Equivalence Evaluations list. This list is most commonly known as the “Orange Book.”
The Orange Book Express mobile app provides users with a mobile-friendly way to identify drug products approved on the basis of safety and effectiveness by the Agency, as well as information about patents and exclusivity. It allows them to search both the Active Ingredient and Proprietary Name fields at once, without searching separately for each marketing status for prescription, over-the-counter, and discontinued products. Users can also search by patent number without specifying a marketing status. The app will differ from the full Web version of the Orange Book in that the ability to filter results and search for text within results will be unavailable via data download.
Orange Book users include pharmacists, prescribers, industry, Agency employees, and third-party payers. Industry personnel refer to the Orange Book for its patent pages and product-specific exclusivity information, and to determine reference standards or drugs for performing their bioequivalence studies. Third-party payers, pharmacists, and prescribers use the Orange Book to determine appropriate generic drug substitution.
The Orange Book first appeared as a print publication in October 1980. Today “Orange Book” is one of the most searched-for terms on FDA.gov.
The Orange Book Express mobile app reflects our commitment to keep up with the latest technologies, developing effective means for the public to access important and useful information about generic drugs. The app also makes the Orange Book available to a wider audience than ever before – supporting users who may not always have convenient access to a computer or wired Internet connection.
I would like to sincerely thank the Office of Generic Drugs and the Office of Communications for their innovative efforts to bring us to another significant milestone in generic drug history. As a result of their work, easy access to real-time information about generics is available. This is especially important for health care professionals who rely on this information in protecting their patients’ health and providing consumers with alternatives to brand name drugs.
For more information about the new mobile app, including links for free download via iTunes or Google Play Store, visit Orange Book.